Asia Pacific Cholesterol Testing Market Through 2025 Rising at 8.2% CAGR with F. Hoffmann-La Roche Ltd, Siemens AG, Accutech, Beckman Coulter, Bio-Rad Laboratories, Prima Lab SA and Abbott

The report covers the present scenario and the growth prospects of the Asia-Pacific cholesterol testing market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

First time buyer? check offers and avail 10% Discount on Direct Purchase "Asia Pacific Cholesterol Testing Market" Or kindly send the email at sopan.gedam@databridgemarketresearch.com

Asia Pacific Cholesterol Testing Market is expected to reach USD 1,959.83 million by 2025 from USD 1,048.15 million in 2017, at a CAGR of 8.2% in the forecast period 2018 to 2025.

Looking for more information on this market? Click Here For Free Sample Copy of Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=asia-pacific-cholesterol-testing-market

The major factors driving the market are technological advancements in cholesterol testing, growing number of cardiovascular diseases and obesity, higher growing number of geriatric population, rising awareness and acceptance of preventive healthcare, increasing cholesterol home/self-testing market. The cholesterol testing market in the Asia Pacific region is leading in China.

Key market players for Asia-Pacific Cholesterol Testing Market are listed below:

• Abbott Laboratories
• Accutech, LLC
• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc.
• Prima Lab SA
• Quest Diagnostics, Inc.
• Home Access Health Corporation
• F. Hoffmann-La Roche AG
• Siemens AG
• Sigma-Aldrich Corp.

Is there any query or specific requirements? Ask to our Industry Expert @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=asia-pacific-cholesterol-testing-market

Market is further segmented into:
• Product Type
• Test
• Test Type
• Prescription Mode
• End-users

The Asia Pacific cholesterol testing market is segmented on the basis of product type, test, test type, prescription mode, and end-users. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.

The Asia-Pacific cholesterol testing market is segmented based on product type into testing strips and test kits. In 2018, test kits segment is expected to dominate the Asia-pacific cholesterol testing market with 62.4% market share and is expected to reach USD 1,231.61 million by 2025, growing at the highest CAGR of 8.3% in the forecast period 2018 to 2025.

The Asia-Pacific cholesterol testing market is segmented on the basis of test into lipid panel test/complete lipid profile, apolipoprotein b test, apolipoprotein A-1 test, APOE genotyping test, apolipoprotein CII and others. In 2018, lipid panel test/complete lipid profile segment is expected to dominate the Asia-pacific cholesterol testing market with 43.0% market share and is expected to reach USD 870.41 million by 2025, growing at the highest CAGR of 8.8% in the forecast period 2018 to 2025.

The Asia-Pacific cholesterol testing market is segmented on the basis of test type into non-invasive and invasive. In 2018, invasive market segment is expected to dominate the Asia-pacific cholesterol testing market with 72.8% market share and is expected to reach USD 1,405.51 million by 2025, growing at a CAGR of 8.0% in the forecast period 2018 to 2025. However, non-invasive is expected to grow at the highest CAGR of 8.8% in the forecast period, and is expected to reach USD 554.32 million in 2025 from USD 283.74 million in 2017.

The Asia-pacific cholesterol testing market is segmented on the basis of prescription mode into over the counter and prescription based. In 2018, prescription based market segment is expected to dominate the Asia-pacific cholesterol testing market with 79.2% market share and is expected to reach USD 1,577.77 million by 2025, growing at the highest CAGR of 8.5% in the forecast period 2018 to 2025.

The Asia-Pacific cholesterol testing market is segmented on the basis of prescription mode into end users, clinics, hospitals, ambulatory centers, homecare and diagnostic centers. In 2018, hospitals are expected to dominate the Asia-pacific cholesterol testing market with 47.2% market share and are expected to reach USD 953.99 million by 2025, growing at the highest CAGR of 8.7% in the forecast period 2018 to 2025.

Based on geography, the Asia-Pacific cholesterol testing market is segmented into geographical regions, such as,
• China,
• Japan,
• India,
• South Korea,
• Australia,
• Thailand,
• Malaysia,
• Singapore,
• Indonesia,
• Philippines
• Rest of APAC

Questions? We’ll Put You On The Right Path Request Analyst Call @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=asia-pacific-cholesterol-testing-market

1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF ASIA-PACIFIC CHOLESTEROL TESTING MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
4.1. DRIVERS
4.2. RESTRAINTS
4.3. OPPORTUNITIES
4.4. CHALLENGES
5. PREMIUM INSIGHTS
6. ASIA-PACIFIC CHOLESTEROL TESTING MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. TESTING STRIPS
6.3. TEST KITS
7. ASIA-PACIFIC CHOLESTEROL TESTING MARKET, BY TEST
7.1. OVERVIEW
7.2. LIPID PANEL TEST/COMPLETE LIPID PROFILE
7.2.1. TOTAL CHOLESTEROL TEST
7.2.2. HDL CHOLESTEROL TEST
7.2.3. LDL CHOLESTEROL TEST
7.2.4. TRIGLYCERIDES/VLDL CHOLESTEROL TEST
7.3. APOLIPOPROTEIN B TEST
7.4. APOLIPOPROTEIN A-1 TEST
7.5. APOE GENOTYPING TEST
7.6. APOLIPOPROTEIN CII
7.7. OTHERS
8. ASIA-PACIFIC CHOLESTEROL TESTING MARKET, BY TEST TYPE
8.1. OVERVIEW
8.2. NON-INVASIVE
8.3. INVASIVE
9. ASIA-PACIFIC CHOLESTEROL TESTING MARKET, BY PRESCRIPTION MODE
9.1. OVERVIEW
9.2. OVER THE COUNTER
9.3. PRESCRIPTION BASED
10. ASIA-PACIFIC CHOLESTEROL TESTING MARKET, BY END-USERS
10.1. OVERVIEW
10.2. CLINICS
10.3. HOSPITALS
10.4. AMBULATORY CENTERS
10.5. HOMECARE
10.6. DIAGNOSTIC CENTERS
10.7. ASIA-PACIFIC
10.7.1. JAPAN
10.7.2. CHINA
10.7.3. INDIA
10.7.4. SOUTH KOREA
10.7.5. AUSTRALIA
10.7.6. SINGAPORE
10.7.7. THAILAND
10.7.8. MALAYSIA
10.7.9. INDONESIA
10.7.10. PHILIPPINES
10.7.11. REST OF ASIA-PACIFIC
11. ASIA-PACIFIC CHOLESTEROL TESTING MARKET, COMPANY LANDSCAPE
11.1. COMPANY SHARE ANALYSIS: ASIA-PACIFIC
12. COMPANY PROFILES
12.1. BIO-RAD LABORATORIES, INC.
12.1.1. COMPANY OVERVIEW
12.1.2. BIO-RAD LABORATORIES, INC.: REVENUE ANALYSIS
12.1.3. PRODUCT PORTFOLIO
12.1.4. RECENT DEVELOPMENTS
12.2. ABBOTT
12.2.1. COMPANY OVERVIEW
12.2.2. ABBOTT: REVENUE ANALYSIS
12.2.3. PRODUCT PORTFOLIO
12.2.4. RECENT DEVELOPMENTS
12.3. SIEMENS AG
12.3.1. COMPANY OVERVIEW
12.3.2. SIEMENS AG: REVENUE ANALYSIS
12.3.3. PRODUCT PORTFOLIO
12.3.4. RECENT DEVELOPMENTS
12.4. ALERE INC.
12.4.1. COMPANY OVERVIEW
12.4.2. ALERE INC.: REVENUE ANALYSIS
12.4.3. PRODUCT PORTFOLIO
12.4.4. RECENT DEVELOPMENTS
12.5. SIGMA ALDRICH (A SUBSIDIARY OF MERCK KGAA)
12.5.1. COMPANY OVERVIEW
12.5.2. MERCK KGAA: REVENUE ANALYSIS
12.5.3. PRODUCT PORTFOLIO
12.5.4. RECENT DEVELOPMENTS
12.6. F. HOFFMANN-LA ROCHE LTD
12.6.1. COMPANY OVERVIEW
12.6.2. F. HOFFMANN-LA ROCHE LTD:REVENUE ANALYSIS
12.6.3. PRODUCT PORTFOLIO
12.6.4. RECENT DEVELOPMENTS
12.7. DANAHER
12.7.1. COMPANY OVERVIEW
12.7.2. DANAHER: REVENUE ANALYSIS
12.7.3. PRODUCT PORTFOLIO
12.7.4. RECENT DEVELOPMENTS
12.8. QUEST DIAGNOSTICS INCORPORATED
12.8.1. COMPANY OVERVIEW
12.8.2. QUEST DIAGNOSTICS INCORPORATED: REVENUE ANALYSIS
12.8.3. PRODUCT PORTFOLIO
12.8.4. RECENT DEVELOPMENTS
12.9. ACCUTECH, LLC
12.9.1. COMPANY OVERVIEW
12.9.2. ACCUTECH, LLC: COMPANY SNAPSHOT
12.9.3. PRODUCT PORTFOLIO
12.9.4. RECENT DEVELOPMENTS
12.10. PRIMA LAB SA
12.10.1. COMPANY OVERVIEW
12.10.2. PRIMA LAB SA: COMPANY SNAPSHOT
12.10.3. PRODUCT PORTFOLIO
12.10.4. RECENT DEVELOPMENTS
12.11. HOME ACCESS HEALTH CORPORATION
12.11.1. COMPANY OVERVIEW
12.11.2. HOME ACCESS HEALTH CORPORATION: COMPANY SNAPSHOT
12.11.3. PRODUCT PORTFOLIO
12.11.4. RECENT DEVELOPMENTS
12.12. EUROFINS SCIENTIFIC
12.12.1. COMPANY OVERVIEW
12.12.2. EUROFINS SCIENTIFIC: REVENUE ANALYSIS
12.12.3. PRODUCT PORTFOLIO
12.12.4. RECENT DEVELOPMENTS
12.13. RANDOX LABORATORIES LTD.
12.13.1. COMPANY OVERVIEW
12.13.2. RANDOX LABORATORIES LTD.: COMPANY SNAPSHOT
12.13.3. PRODUCT PORTFOLIO
12.13.4. RECENT DEVELOPMENTS
12.14. PTS DIAGNOSTICS
12.14.1. COMPANY OVERVIEW
12.14.2. PTS DIAGNOSTIC: COMPANY SNAPSHOT
12.14.3. PRODUCT PORTFOLIO
12.14.4. RECENT DEVELOPMENTS
13. RELATED REPORTS

Looking for more insights from this report? click the link below: http://databridgemarketresearch.com/reports/asia-pacific-cholesterol-testing-market/

Related Report

Global Heat-Treated Steel Plates Market– Industry Trends and Forecast to 2025

Global Heat-Treated Steel Plates Market, By Steel Type (Carbon, Alloy, and Stainless), By Treatment (Quenching & Tempering, Normalizing, and Stress Relieving), By Application (Construction, Energy, Industrial Machinery), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)– Industry Trends and Forecast to 2025

http://databridgemarketresearch.com/reports/global-heat-treated-steel-plates-market/

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.